+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 10 Actively Recruiting clinical trials

G

Actively Recruiting

Researchers are conducting a non-interventional translational research study to examine the genetic and transcriptomic features of patients with non-small cell lung cancer NSCLC. The study focuses on analyzing tumor and blood samples to uncover genomic changes, mutational patterns, and gene expression profiles linked to patient outcomes and responses to immunotherapy. Approximately 300 patients with confirmed NSCLC, including both early-stage and metastatic cases, will participate. Participants will provide formalin-fixed paraffin-embedded FFPE tumor tissue and blood samples. Some may also provide fresh frozen tumor samples. The study includes whole-exome sequencing and RNA sequencing to identify clinically relevant genetic alterations, tumor mutational burden, and immune-related gene signatures. A smaller subgroup of about 20 patients with unresectable stage III NSCLC will be followed in a pilot sub-study to analyze circulating tumor DNA ctDNA over time during and after chemoradiation and durvalumab maintenance therapy. Throughout the study, researchers will collect tumor tissue, blood, and plasma samples at various timepoints. They will analyze these samples for molecular markers and track changes in ctDNA in the sub-study group. The main outcomes include the prevalence of genomic alterations, tumor mutational burden, and immune subtypes at baseline. The study aims to enhance understanding of NSCLC biology and support the discovery of biomarkers for prognosis and immunotherapy response. The study is expected to continue until the end of 2026.

Age: 18Years +All Genders
20 locations
P

Actively Recruiting

Researchers are investigating a new way to personalize radiotherapy and androgen deprivation therapy ADT duration for men with high-risk localized prostate cancer. This single-arm, phase II study uses advanced artificial intelligence to classify patients and tailor treatment. The goal is to shorten ADT duration while maintaining effective disease control and potentially reducing side effects compared to current guidelines. Participants will receive a combination of treatments starting with a high-dose-rate brachytherapy HDR BT boost to the prostate, delivering 15 Gray in a single fraction. After a break of about two weeks, they will undergo stereotactic body radiation therapy SBRT delivering 25 Gray in five daily fractions to the prostate and seminal vesicles. Alongside radiation, patients will take androgen deprivation therapy for 12 months, given concurrently and as an adjuvant. During the study, participants will have regular assessments including imaging scans, biopsies, and quality of life questionnaires. Researchers will monitor disease-free survival at five years as the primary outcome, along with secondary measures such as local or regional failure, metastatic-free survival, overall survival, prostate cancer-specific survival, biochemical failure, and treatment-related toxicities. Testosterone recovery and quality of life will also be evaluated up to five years after treatment completion.

Age: 18Years +MALEPhase 2
1 location
P

Actively Recruiting

Researchers are investigating a new approach to personalize radiation therapy for men with high-risk localized prostate cancer using multimodal artificial intelligence MMAI. This phase II study evaluates a combination of treatments including prostate dose escalation with high-dose-rate HDR brachytherapy, two years of androgen deprivation therapy ADT, and ultra-hypofractionated whole-pelvis radiotherapy UHF-RT. The goal is to assess treatment safety and cancer control outcomes in this specific patient group. All participants will receive a standardized treatment regimen involving a single fraction of HDR brachytherapy delivering 15 Gy to the prostate, followed by ultra-hypofractionated external beam radiotherapy to the elective pelvic lymph nodes at 25 Gy over five fractions. Alongside radiation, patients will undergo two years of ADT using luteinizing hormone-releasing hormone agonists or antagonists. The radiation techniques include intensity-modulated and image-guided radiotherapy. This study lasts about three weeks for radiation delivery, with ADT continuing for 24 months. Participants will be monitored closely for side effects and cancer progression over a minimum of five years. Regular assessments will include toxicity evaluations, survival measures, quality of life questionnaires, and blood tests including testosterone levels. Researchers will also analyze MMAI-based risk predictions and seek biomarkers to improve treatment personalization. Follow-up visits are scheduled frequently during and after treatment to track outcomes and safety.

Age: 18Years +MALEPhase 2
1 location
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the NeoPill oral hygiene device to see if it can reduce the amount of aerobic bacteria in the mouths of adults wearing fixed orthodontic appliances like braces. Maintaining good oral hygiene can be difficult for these patients due to limited access around brackets and wires. This single-arm clinical evaluation aims to provide preliminary data on how well the device works and how users experience it. The NeoPill is a reusable, battery-operated device that mechanically cleans the mouth without using chemicals. In this study, trained staff will apply the NeoPill inside the mouth for 30 seconds during a single visit. Oral swab samples will be taken immediately before and after using the device to measure changes in bacterial load. Participants will also complete a questionnaire about the devices comfort, usability, and overall experience. Participants will provide oral swab samples from specific areas around their braces, which are sent to a laboratory to count bacterial colonies. The main measurement is the difference in bacterial load before and after device use. Safety is monitored by noting any temporary discomfort. The study collects and stores data securely and anonymizes results. The entire participation occurs in one visit, focusing on both laboratory results and user feedback.

Age: 18Years +All GendersPhase Not Applicable
1 location
C

Actively Recruiting

Researchers are comparing two advanced imaging techniques, MRI-RSI and PSMA PETCT, with the current standard multiparametric MRI mpMRI to improve the detection and outlining of tumors inside the prostate in men newly diagnosed with primary prostate cancer. This study focuses on men with intermediate to very high-risk prostate cancer to assess how these imaging methods may better identify the tumor burden and reduce variability between observers. The goal is to enhance personalized treatment planning for prostate cancer patients. Participants will undergo MRI-RSI imaging, PSMA PETCT scans, and MR-guided transrectal ultrasound TRUS prostate biopsies following standard protocols. The study will prospectively compare these imaging methods to evaluate their effectiveness in detecting and outlining tumors. These tests are non-invasive or minimally invasive diagnostic procedures conducted before any systemic therapy. During the 24-month study period, researchers will measure how well each imaging method detects tumors, including sensitivity, specificity, and tumor volume measurements. They will also assess the agreement between observers and the relationship between imaging results and radiation dose planning. Participants will be monitored throughout the study to collect imaging data and biopsy results, supporting a thorough evaluation of each techniques usefulness in prostate cancer care.

Age: 18Years +MALEPhase Not Applicable
1 location
P

Actively Recruiting

Researchers are conducting an international, multi-center, randomized, open-label phase III trial to compare elacestrant with standard endocrine therapy in patients with ER-positive, HER2-negative breast cancer who have relapse detected by circulating tumor DNA ctDNA. The study focuses on patients who show ctDNA in their blood but have no distant metastasis, aiming to evaluate treatment outcomes and disease progression. This trial involves a screening phase to monitor ctDNA presence and a randomized treatment phase for eligible patients. During the ctDNA screening phase, patients receive standard adjuvant endocrine therapy, such as tamoxifen or aromatase inhibitors, and undergo plasma testing every six months for up to approximately 5.7 years. Patients who test ctDNA-positive undergo imaging to rule out metastasis and, if eligible, are randomized within four weeks to either continue their current endocrine treatment or receive elacestrant at 400 mg daily orally. Treatment duration varies based on prior endocrine therapy length, lasting between 2 and 7 years. Follow-up includes frequent ctDNA testing and imaging over three years to monitor disease status. Participants will have plasma samples collected regularly during screening and follow-up. Imaging assessments such as mammograms, bone scans, and CT scans are performed to detect metastases or recurrences. Researchers will track distant metastasis-free survival and other outcomes including overall survival, disease recurrence, adverse events, and quality of life over extended periods, up to 11.7 years. The study ensures ongoing monitoring and safety evaluations throughout treatment and follow-up until study completion.

Age: 18Years +All GendersPhase 3
113 locations
R

Actively Recruiting

Healthy Volunteer

Researchers are evaluating an intervention that combines behavioral recommendations and technical measures to reduce exposure to heat and air pollution and related health effects in pregnant women aged 20 to 35 years. The study aims to determine whether these interventions reduce personal ambient temperature exposure using a wearable device, lower indoor air pollution using air quality sensors, and improve sleep quality measured by the Pittsburgh Sleep Quality Index. Participants are randomly assigned to one of three groups a control group with no alerts or recommendations, a heat intervention group receiving personal alerts and advice via mobile and online tools to reduce heat exposure, and a combined heat and air pollution intervention group receiving alerts and recommendations plus continuous use of air cleaners with HEPA filters at home and work. The intervention period lasts for two months, during which participants carry out their daily activities. Throughout the study, participants wear a device for continuous temperature monitoring, have their core temperature measured three times, and complete sleep quality questionnaires at baseline, one month, and two months. Researchers also collect blood and urine samples to assess various biomarkers and monitor vital signs like heart rate and blood pressure. Multiple environmental and physiological measures are tracked daily to evaluate the interventions effects on sleep, anxiety, and exposure to pollutants.

Age: 20Years - 35YearsFEMALEPhase Not Applicable
3 locations
O

Actively Recruiting

Researchers are evaluating treatment outcomes in elderly patients aged 65 years and older with locally advanced head-and-neck squamous cell carcinomas HNSCC involving the oral cavity, oropharynx, hypopharynx, or larynx. The study aims to determine how definitive chemo-radiotherapy affects overall survival and progression-free survival in this vulnerable population, considering factors like age, performance status, and comorbidities. This retrospective multinational multicenter study addresses the limited evidence on optimal care for these patients. The study observes patients who have undergone definitive chemo-radiotherapy since 2005, focusing on modern radiotherapy techniques such as intensity-modulated radiotherapy IMRT and varying chemotherapy schedules, including weekly cisplatin. It assesses the impact of these treatments on survival outcomes and investigates the role of concomitant chemotherapy in this elderly cohort. Participants medical records are reviewed to collect data on overall survival up to five years and progression-free survival up to five years after treatment initiation. Researchers analyze patient characteristics, treatment details, and outcomes to understand the influence of therapy choices on survival. The study involves no new interventions or procedures, relying on existing clinical data from multiple centers.

Age: 65Years +All Genders
18 locations
R

Actively Recruiting

Researchers are studying genetic modifiers in hemoglobinopathies, including sickle cell disease and beta-thalassemia, through a large-scale, multi-ethnic genome-wide association study GWAS. These diseases vary widely in severity, influenced partly by genetic factors. The study aims to discover new genetic modifiers, validate known ones, pool existing genomic data, standardize disease descriptions, create a comprehensive research resource, and develop risk scores to help stratify patients based on disease severity and treatment response. The study will collect blood samples during routine clinical visits to perform GWAS experiments on individuals with hemoglobinopathies. Participants include those with various genotypes of sickle cell disease, beta-thalassemia, and alpha-thalassemia, without restrictions on gender or ethnicity. All participants will provide consent, and DNA samples may be collected if not already available in existing biobanks. Participants will contribute data including genetic, phenotypic, and functional information. The study will analyze worldwide patient demographics, genotypes, and disease severity. Researchers will investigate genetic modifiers related to survival, neurological function, renal impairment, pain syndromes, pulmonary hypertension, and treatment responses. This observational study involves data collection over five years, with no investigational treatments administered.

Age: 2Years +All Genders
26 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are conducting a study called EUthyroid2 to develop and implement educational programs in schools across the UK, Germany, Slovenia, the Republic of Cyprus, Bangladesh, and Pakistan. The goal is to raise awareness about the risks of iodine deficiency, which is a major preventable cause of thyroid problems and developmental issues in children. This project focuses on adolescents aged 13 to 17 years and aims to reduce the impact of iodine deficiency in these populations. The study implements an educational intervention using materials such as the Iodine Feedback Tool, lectures about iodine and health, booklets, exercises, group assignments, and a dedicated webpage. Each participating country will apply the intervention in three types of schools secondary, high, and vocational schools. The intervention and its effects will be measured at three time points before the program starts, 2 to 4 weeks after, and again 6 to 8 months later. Participants will be involved through baseline and follow-up questionnaires assessing their awareness of iodine deficiency and their iodine intake. Teachers and students will also take part in online surveys and semi-structured interviews to evaluate the implementation process. The study will analyze changes over time and differences between school types, genders, and age groups. Overall, the study duration for each participant spans from the initial assessment to the last follow-up several months later.

Age: 13Years - 17YearsAll GendersPhase Not Applicable
6 locations